Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2/3 1

Status

Unknown 2Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Gastrointestinal 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Completed × rofecoxib × Clear all
NCT00060476 2017-05-09

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Merck Sharp & Dohme LLC

Phase 3 Completed
15,000 enrolled
Genitourinary

Prostatic Neoplasms

NCT00031863 2013-08-02

Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer

National Cancer Institute (NCI)

Phase 3 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡